Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $6.2B | $1.3B | $187M | $384M | 24.9% | -2.9% | -78.4% |
| 2024 | $6.4B | $1.6B | $864M | $588M | 183.1% | 2.2% | -15.5% |
| 2023 | $6.3B | $1.4B | $1.0B | $538M | -1461.4% | 1.4% | 11.6% |
| 2022 | $6.2B | $1.8B | $917M | $431M | -102.8% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 6,174 | 6,263 | 6,403 | 6,216 |
| Operating Revenue | - | 6,174 | 6,263 | 6,403 | 6,216 |
| Cost Of Revenue | - | 2,294 | 2,515 | 2,688 | 2,903 |
| Gross Profit | - | 3,880 | 3,748 | 3,715 | 3,313 |
| Operating Expense | - | 2,175 | 2,421 | 2,229 | 2,087 |
| Research And Development | - | 471 | 528 | 469 | 366 |
| Selling General And Administration | - | 1,704 | 1,893 | 1,760 | 1,721 |
| Total Expenses | - | 4,469 | 4,936 | 4,917 | 4,990 |
| Operating Income | - | 1,705 | 1,327 | 1,486 | 1,226 |
| EBITDA | - | 1,756 | 1,436 | 1,604 | 1,290 |
| Normalized EBITDA | - | 1,902 | 1,548 | 1,742 | 1,706 |
| EBIT | - | 1,544 | 1,200 | 1,327 | 929 |
| Interest Expense | - | 422 | 527 | 520 | 504 |
| Net Interest Income | - | -422 | -527 | -520 | -504 |
| Other Non Operating Income Expenses | - | -15 | -15 | -21 | 119 |
| Other Income Expense | - | -161 | -127 | -159 | -297 |
| Interest Expense Non Operating | - | 422 | 527 | 520 | 504 |
| Net Non Operating Interest Income Expense | - | -422 | -527 | -520 | -504 |
| Pretax Income | - | 1,122 | 673 | 807 | 425 |
| Tax Provision | - | 205 | -350 | -57 | 238 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -26.72 | -23.52 | -28.98 | -87.36 |
| Net Income Continuous Operations | - | 917 | 1,023 | 864 | 187 |
| Net Income From Continuing And Discontinued Operation | - | 917 | 1,023 | 864 | 187 |
| Net Income From Continuing Operation Net Minority Interest | - | 917 | 1,023 | 864 | 187 |
| Net Income | - | 917 | 1,023 | 864 | 187 |
| Net Income Common Stockholders | - | 917 | 1,023 | 864 | 187 |
| Net Income Including Noncontrolling Interests | - | 917 | 1,023 | 864 | 187 |
| Normalized Income | - | 1,036.28 | 1,111.48 | 973.02 | 515.64 |
| Diluted NI Availto Com Stockholders | - | 917 | 1,023 | 864 | 187 |
| Basic Average Shares | - | 254.08 | 255.24 | 257.05 | 259.50 |
| Diluted Average Shares | - | 255.17 | 256.27 | 259.15 | 260.76 |
| Reconciled Depreciation | - | 212 | 236 | 277 | 361 |
| Reconciled Cost Of Revenue | - | 2,294 | 2,515 | 2,688 | 2,903 |
| Total Unusual Items | - | -146 | -112 | -138 | -416 |
| Total Unusual Items Excluding Goodwill | - | -146 | -112 | -138 | -416 |
| Net Income Discontinuous Operations | 0 | 0 | 0 | - | - |
| Special Income Charges | - | -135 | -70 | -112 | -402 |
| Other Special Charges | - | 107 | 8 | 81 | 6 |
| Impairment Of Capital Assets | - | - | 0 | 0 | 301 |
| Restructuring And Mergern Acquisition | - | 28 | 62 | 31 | 95 |
| Gain On Sale Of Security | - | -11 | -42 | -26 | -14 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Organon & Co.this co. | OGN | $3.5B | 18.82↓ discount | 4.68 | 24.9% | 8.98 |
| Waystar Holding Corp. | WAY | $3.9B | 34.60 | 1.00 | 2.9% | 13.55 |
| Catalyst Pharmaceuticals, Inc. | CPRX | $3.8B | 17.87 | 4.01 | 22.5% | 10.56 |
| Merit Medical Systems, Inc. | MMSI | $3.8B | 29.27 | 2.37 | 8.1% | 12.46 |
| ACADIA Pharmaceuticals Inc. | ACAD | $3.7B |
| - |
| - |
| - |
| - |
| 9.51 |
| 3.03 |
| 31.9% |
| 30.83 |
| ICU Medical, Inc. | ICUI | $3.4B | 4607.08 | 1.59 | 0.0% | 14.73 |
| Concentra Group Holdings Parent, Inc. | CON | $3.2B | 19.16 | 8.11 | 42.3% | 12.74 |
| Integer Holdings Corporation | ITGR | $3.1B | 30.63 | 1.80 | 5.9% | 15.20 |
| Arcus Biosciences, Inc. | RCUS | $3.1B | -8.80 | 4.92 | -55.9% | -8.94 |
| Peer Median | - | 24.21 | 2.70 | 7.0% | 13.15 | |
Historically, Apr has averaged the highest return (+20.9%); Nov the lowest (-9.2%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +19.1%Positive MonthJan 2026: +19.11% | -14.6%Negative MonthFeb 2026: -14.64% | -17.8%Negative MonthMar 2026: -17.83% | +121.2%Positive MonthApr 2026: +121.20% | +0.7%Neutral MonthMay 2026: +0.68% | +1.5%Neutral MonthJun 2026: +1.50% | +0.1%Neutral MonthJul 2026: +0.07% | +1.3%*Neutral MonthAug 2026: +1.33% | — | — | — | — |
| 2025 | +4.3%Positive MonthJan 2025: +4.29% | -4.2%Negative MonthFeb 2025: -4.18% | -0.1%Neutral MonthMar 2025: -0.13% | -13.2%Negative MonthApr 2025: -13.16% | -28.7%Negative MonthMay 2025: -28.69% | +5.0%Positive MonthJun 2025: +4.99% | +0.2%Neutral MonthJul 2025: +0.21% | -2.9%Negative MonthAug 2025: -2.89% | +13.4%Positive MonthSep 2025: +13.38% | -36.8%Negative MonthOct 2025: -36.80% | +14.2%Positive MonthNov 2025: +14.22% | -7.0%Negative MonthDec 2025: -7.00% |
| 2024 | +15.5%Positive MonthJan 2024: +15.46% | +4.6%Positive MonthFeb 2024: +4.56% | +8.0%Positive MonthMar 2024: +7.98% | -1.0%Neutral MonthApr 2024: -1.01% | +14.6%Positive MonthMay 2024: +14.62% | -3.0%Negative MonthJun 2024: -2.95% | +5.6%Positive MonthJul 2024: +5.60% | +2.2%Positive MonthAug 2024: +2.24% | -14.4%Negative MonthSep 2024: -14.41% | -1.8%Neutral MonthOct 2024: -1.83% | -15.5%Negative MonthNov 2024: -15.50% | -6.0%Negative MonthDec 2024: -5.99% |
| 2023 | +7.9%Positive MonthJan 2023: +7.88% | -18.7%Negative MonthFeb 2023: -18.72% | -4.0%Negative MonthMar 2023: -3.96% | +4.7%Positive MonthApr 2023: +4.72% | -21.3%Negative MonthMay 2023: -21.27% | +7.3%Positive MonthJun 2023: +7.32% | +5.6%Positive MonthJul 2023: +5.62% | -0.1%Neutral MonthAug 2023: -0.09% | -20.9%Negative MonthSep 2023: -20.95% | -14.8%Negative MonthOct 2023: -14.80% | -23.5%Negative MonthNov 2023: -23.46% | +27.4%Positive MonthDec 2023: +27.39% |
| 2022 | +4.8%Positive MonthJan 2022: +4.79% | +17.0%Positive MonthFeb 2022: +16.99% | -6.4%Negative MonthMar 2022: -6.43% | -7.4%Negative MonthApr 2022: -7.44% | +17.4%Positive MonthMay 2022: +17.41% | -11.1%Negative MonthJun 2022: -11.09% | -6.0%Negative MonthJul 2022: -6.01% | -10.1%Negative MonthAug 2022: -10.06% | -18.0%Negative MonthSep 2022: -17.98% | +11.9%Positive MonthOct 2022: +11.88% | -0.6%Neutral MonthNov 2022: -0.61% | +7.3%Positive MonthDec 2022: +7.34% |
| 2021 | — | — | — | — | — | -15.4%Negative MonthJun 2021: -15.36% | -4.1%Negative MonthJul 2021: -4.13% | +16.8%Positive MonthAug 2021: +16.82% | -3.2%Negative MonthSep 2021: -3.25% | +12.1%Positive MonthOct 2021: +12.08% | -20.5%Negative MonthNov 2021: -20.46% | +4.2%Positive MonthDec 2021: +4.17% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
